Shares of Voyager Therapeutics, Inc. (VYGR) is gaining over 16% on Monday morning after Neurocrine Biosciences and Voyager Therapeutics announced a collaboration deal for development and commercialization of Voyager's GBA1 program.
VYGR is currently trading at $8.08, up $1.12 or 16.14%, on the Nasdaq. The stock opened its trading at $8.63 after closing Friday's trading at $6.96. The stock has traded between $2.60 and $10.60 in the past 52-week period.
Voyager Therapeutics announced a deal with Neurocrine Biosciences Inc. (NBIX) to develop and commercialize gene therapies, including one that is being tested as a treatment for Parkinson's disease.
The collaboration includes Voyager's preclinical, intravenously administered GBA1 gene therapy program for Parkinson's disease and other GBA1-mediated diseases, which combines a GBA1 gene replacement payload with novel capsids from Voyager's TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform.
In addition, Neurocrine Biosciences and Voyager have agreed to collaborate on three new gene therapy programs directed to rare CNS targets, each also leveraging Voyager's novel TRACER capsids. The collaboration builds upon the long-standing strategic partnership between Neurocrine Biosciences and Voyager and continues to combine Voyager's expertise in novel capsid discovery, payload design, and neuropharmacology with Neurocrine Biosciences' expertise in neuroscience and the clinical and commercial development of therapies for patients suffering from serious neurological diseases.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.